Promising data in advanced bladder cancer and the need for other treatments for superficial bladder cancer led to the study of gemcitabine by intravesical administration in superficial bladder cancer but although the CHMP acknowledged that gemcitabine has shown activity in non-muscle invasive bladder cancer in intermediate and high risk patients, no actual data from Phase III trials has been submitted.